“Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States”

“Melinta Therapeutics, Inc., a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, has announced the U.S. launch of intravenous and oral formulations of Baxdela™ (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.

Approximately 14 million patients are treated for serious skin infections each year, either in the hospital or community settings, and these are often caused by MRSA.

“The launch of Baxdela is a significant milestone for Melinta – one that comes on the heels of a very successful year, cementing our leadership position in the antibiotics space,” stated Dan Wechsler, president & chief executive officer of Melinta. “I would especially like to thank the doctors and patients around the world that participated in our Baxdela clinical trial program, as well as the Melinta team that has worked tirelessly over many years to bring Baxdela to the market. It is because of their dedication that we are able to offer patients and healthcare providers this new treatment option.”

Melinta will market Baxdela nationwide leveraging an industry-leading commercial sales team. Baxdela joins a strong portfolio of infectious disease products that will be marketed by Melinta, including Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for injection.”

Source: Global Newswire


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed